Acute immune thrombocytopenic purpura

Summary

Immune thrombocytopenia in children is usually a self-limiting illness, but in adults the disease is likely to be chronic, and may be associated with other pathology which predisposes to bleeding. Despite very low platelet counts serious bleeding is rare in both adults and children. More than 80% of children have mild clinical manifestations. Intracranial haemorrhage is rare at all ages, is unpredictable and can occur at any time when the count is very low. Currently recommended therapies for both adults and children are associated with significant side effects and occasional deaths. Treatment may interfere with quality of life more than the illness itself. Drugs can be withheld in the majority of children with appropriate advice to child and family. Treatment can be individualised, taking into account the person’s needs and lifestyle as well as bleeding. In chronic ITP many need no active therapy. The situation with adults is more complex but those with a platelet count above 30 x 10⁹/l usually need no treatment as bleeding is rare, and those adults with refractory ITP unresponsive to treatment live with very low counts for years without significant bleeding suggesting the need to re-evaluate the balance of risks of treatment versus bleeding. It is notable that adults with ITP may die from infection, probably related to therapy.

Keywords

ITP - thrombocytopenia

• References

• 1 Buchanan GR. Bleeding signs in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25: S42-46.
• 2 Beck CE, Nathan PC, Parkin PC. et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 2005; 147: 521-527.
• 3 Bolton-Maggs PH, Dickerhoff R, Vora AJ. The nontreatment of childhood ITP (or „the art of medicine consists of amusing the patient until nature cures the disease“). Semin Thromb Hemost 2001; 27: 269-275.
• 4 Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997; 350: 620-623.
• 5 Bolton-Maggs PHB, Moon I. National audit of the Management of Childhood Idiopathic Thrombocytopenic Purpura against UK Guidelines: closing the loop – education and re-audit demonstrate a change in practice. Blood 2001; 98: 58b.
• 6 Bussel JB, Cheng G, Saleh MN. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-2247.
• 7 Carcao MD, Zipursky A, Butchart S. et al. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998; 424: 71-74.
• 8 Cooper N, Evangelista ML, Amadori S. et al. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?. Curr Opin Hematol 2007; 14: 642-646.
• 9 Cooper N, Stasi R, Cunningham-Rundles S. et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125: 232-239.
• 10 Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000; 95: 2523-2529.
• 11 George JN, Woolf SH, Raskob GE. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
• 12 Klaassen RJ, Blanchette VS, Barnard D. et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids’ ITP Tools. J Pediatr 2007; 150: 510-515.
• 13 Kuhne T, Buchanan GR, Zimmerman S. et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003; 143: 605-608.
• 14 Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616.
• 15 Lilleyman JS. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology. Arch Dis Child 1994; 71: 251-253.
• 16 Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr 1998; 133: 334-339.
• 17 Portielje JE, Westendorp RG, Kluin-Nelemans HC. et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-2554.
• 18 Rosthoj S, Hedlund-Treutiger I, Rajantie J. et al. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: A prospective Nordic study of an unselected cohort. J Pediatr 2003; 143: 302-307.
• 19 Sutor AH, Harms A, Kaufmehl K. Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany. Semin Thromb Hemost 2001; 27: 253-267.
• 20 Watson S, Bolton-Maggs PHB. Management strategies in immune thrombocytopenic purpura (ITP) – more than medication – What do the patients think?. Blood 2000; 96: 438a.